Dr. David Miller, MD
Claim this profileParkland Memorial Hospital
Expert in Parotid Gland Cancer
Studies Cervical Adenocarcinoma
21 reported clinical trials
40 drugs studied
About David Miller, MD
Education:
- Earned an MD (Doctor of Medicine) from the University of Oklahoma–Tulsa.
Experience:
- Completed a residency in obstetrics and gynecology at the Medical College of Pennsylvania (now Drexel University College of Medicine).
- Undertook fellowships in reproductive endocrinology and gynecologic oncology at the University of California, San Diego, and Stanford University Medical Center, respectively.
- Board certified in obstetrics and gynecology and gynecologic oncology.
- Has been a faculty member at UT Southwestern since 1991, holding positions such as Chief of the Division of Gynecologic Oncology and Medical Director for the Division of Gynecologic Oncology at the Harold C. Simmons Comprehensive Cancer Center.
- Actively involved in research, clinical trials, and has published several academic articles in the field of gynecologic oncology.
Area of expertise
1Parotid Gland Cancer
Global LeaderStage IV
Stage II
Stage III
2Cervical Adenocarcinoma
Stage IV
Stage III
Stage II
Affiliated Hospitals
Clinical Trials David Miller, MD is currently running
ACR-368
for Ovarian Cancer
This trial tests a new drug, ACR-368, alone or with a small dose of another drug, gemcitabine, in patients whose cancers don't respond to standard treatments. A special test helps decide which treatment might work best for each patient. Gemcitabine has been used with other drugs for various cancers, including pancreatic, lung, ovarian, and breast cancers.
Recruiting1 award Phase 210 criteria
Selinexor Maintenance Therapy
for Endometrial Cancer
The purpose of this study is to evaluate the efficacy and safety of selinexor as a maintenance treatment in patients with p53 wt endometrial carcinoma (EC), who have achieved a partial response (PR) or complete response (CR) (per Response Evaluation Criteria in Solid Tumors version 1.1 \[RECIST v 1.1\]) after completing at least 12 weeks of platinum-based therapy. A total of 220 participants will be enrolled in the study and randomized in a 1:1 ratio to maintenance therapy with either selinexor or placebo.
Recruiting1 award Phase 32 criteria
More about David Miller, MD
Clinical Trial Related2 years of experience running clinical trials · Led 21 trials as a Principal Investigator · 3 Active Clinical TrialsTreatments David Miller, MD has experience with
- Selinexor
- Letrozole
- External Beam Radiation Therapy
- Pembrolizumab
- Cisplatin
- Quality-of-Life Assessment
Breakdown of trials David Miller, MD has run
Parotid Gland Cancer
Cervical Adenocarcinoma
Ovarian Cancer
Serous Cystadenocarcinoma
Endometrial Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
What does David Miller, MD specialize in?
Is David Miller, MD currently recruiting for clinical trials?
Are there any treatments that David Miller, MD has studied deeply?
What is the best way to schedule an appointment with David Miller, MD?
What is the office address of David Miller, MD?
Is there any support for travel costs?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.